OCULAR THERAPEUTIX, INC: directors' dealings · United States · SEC (Form 4)

About OCULAR THERAPEUTIX, INC

Ocular Therapeutix, Inc. is a U.S.-based biopharmaceutical company listed on the NASDAQ Global Market under the ticker OCUL, with headquarters in Bedford, Massachusetts, United States. Founded in 2006, the company was built around a proprietary biodegradable hydrogel platform designed to improve the local delivery of ophthalmic therapies. Its business model combines a commercial product with a late-stage development pipeline, giving it a hybrid profile that sits between a revenue-generating eye-care company and a clinical-stage biotech. The company’s core focus is ophthalmology, with particular strength in retinal disease and perioperative eye-care treatments. Its lead marketed product is DEXTENZA, a dexamethasone ophthalmic insert approved by the FDA for the treatment of ocular pain and inflammation following ophthalmic surgery, as well as ocular itching associated with allergic conjunctivitis. DEXTENZA is commercialized in the United States through specialty distributors, ambulatory surgery centers, hospital outpatient departments, and physicians’ offices. It remains the company’s only revenue-producing product and is important strategically, although sales have been influenced by reimbursement pressure, rebates, and pricing dynamics. Beyond DEXTENZA, Ocular Therapeutix is most notable for its late-stage pipeline. AXPAXLI is the company’s key development asset: an axitinib-based program delivered through the ELUTYX hydrogel platform, currently being studied in Phase 3 registrational trials for wet age-related macular degeneration (wet AMD) and diabetic retinal disease, including non-proliferative diabetic retinopathy. The company is also developing OTX-TIC, an intracameral travoprost hydrogel for glaucoma and ocular hypertension, which has completed Phase 2. This pipeline reflects a clear strategy of building differentiated, long-acting, locally delivered therapies aimed at improving efficacy, convenience, and adherence. From a competitive standpoint, Ocular Therapeutix operates in a crowded ophthalmology market where it faces large pharmaceutical companies, specialist retina players, and a number of well-funded biotech peers. Its differentiation rests on its hydrogel drug-delivery technology, the potential convenience of extended-release administration, and the fact that it already has an approved commercial asset. Geographically, the company remains primarily U.S.-centric, but it also has international licensing arrangements, including partnerships with AffaMed covering certain Asian territories for DEXTENZA and OTX-TIC. Recent developments have been important for investors. In 2025, the company strengthened its balance sheet through a large equity offering and continued advancing its Phase 3 AXPAXLI program. It also expanded the clinical and regulatory discussion around its retinal assets, which could be material to long-term valuation. As with most biotech names, the investment case remains highly sensitive to clinical readouts, FDA interactions, reimbursement trends, and the commercial trajectory of DEXTENZA.